Adviser, broker charged by SEC with insider trading

King Pharmaceuticals-Pfizer deal led to nearly $500,000 in illegal profits, agency claims.
SEP 25, 2013
New York financial adviser Tibor Klein and a friend, a Florida broker, earned more than $437,000 in illegal profits for themselves and clients by trading shares of King Pharmaceuticals after they were tipped that the drug firm would be purchased by giant Pfizer Inc., securities regulators said Friday. The Securities and Exchange Commission alleged that Mr. Klein, president of Klein Financial Services, began purchasing King Pharmaceuticals shares on the first trading day after he learned about the merger from a client who does legal work for the company. After the merger was announced Oct. 12, 2010, the stock's price rose 39% and Mr. Klein sold shares in his and in clients' accounts to generate profits of $328,375, the SEC said in its complaint. Mr. Klein also tipped his best friend Michael Shechtman, a stockbroker who lives in Florida, after learning about the deal, the SEC said. Mr. Shechtman then purchased shares and options in his and his wife's accounts, the commission said. Mr. Shechtman sold those shares and options after the deal was announced and shares rose, earning him about $109,040 in illegal profits, according to the complaint filed in the U.S. District Court for the Southern District of Florida. “As securities industry professionals, Klein and Shechtman clearly know the difference between legal and illegal trading,” said Eric I. Bustillo, director of the SEC regional office in Miami. “Instead of playing by the rules, they chose to exploit nonpublic information for an easy payday, but they didn't plan on getting caught by the SEC.” Neither Mr. Klein's lawyer, Tucker Byrd, nor Mr. Shechtman's lawyer, Jim Sallah, returned calls seeking comment. The SEC said there were many more calls than normal between the two friends over the days involved. The complaint also said that Mr. Shechtman had never traded in options before the trades noted in this case.

Latest News

GLP-1 users are trading retirement savings for their prescriptions
GLP-1 users are trading retirement savings for their prescriptions

A Nationwide survey finds 47% of GLP-1 users have never discussed the drugs’ financial impact with an advisor, even as many dip into savings.

Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors
Inspired Healthcare sale price of properties is 59% of $1.2 billion sold by advisors

The hundreds of millions of dollars from a sale of Inspired Healthcare properties does not mean an immediate windfall for investors.

Class action alleges Webull misled investors about China operations
Class action alleges Webull misled investors about China operations

Its SEC filings said one thing - a congressional probe said another.

Investors accuse Netcapital of inflating revenue through sham deals
Investors accuse Netcapital of inflating revenue through sham deals

Sham agreements allegedly padded revenue by 345%.

Pre-retirees are looking for flexibility, security, and guidance when it comes to retirement income: Cerulli
Pre-retirees are looking for flexibility, security, and guidance when it comes to retirement income: Cerulli

"Most pre-retirees are uncomfortable making key retirement income decisions without an advisor's help," said Chris Bailey of Cerulli.

SPONSORED Built on insurance experience to deliver on long-term promises

Knighthead Life entered the market with a competitive MYGA. A strong launch earned advisor confidence and paved the way for FIAs.

SPONSORED In the Age of AI, Trust Becomes the Advisor's Greatest Asset

As AI makes financial information more accessible than ever, Lana Hock explains why human judgment, trust, and empathy remain the qualities clients value most in a financial advisor